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Hepatitis during antituberculosis treatmentDear Editor,
We read with great interest the article by Sun et al.1
They prospectively investigated 261 adult patients who
underwent antituberculosis treatment with different
co-morbidities. By using multivariate analysis, the authors
identified that abnormal baseline liver function tests and
liver cirrhosis were independent factors associated with
development of hepatitis. Because of the inclusion criteria
adopted, the patient characteristics in this study mimicked
real-world practice and hence their findings provide novel
information to the practicing physician. However, some
issues are worthy of further discussion.
First, the definition of liver cirrhosis was not clearly
described. It is generally believed that ultrasound findings
are operator dependent and it may not be accurate to
define “liver cirrhosis”.2 In contrast, liver biopsy is more
accurate for defining liver cirrhosis and to assess its
severity.3 Therefore discrepancies might exist between
these two diagnostic modalities and the authors should
clarify these issues to improve the precise interpretation of
clinical results.
Second, the American Thoracic Society suggests
a routine screening for viral hepatitis in endemic areas as
pretreatment evaluation for tuberculosis patients.4
Previous studies also indicated that chronic hepatitis B
may serve as a risk factor for more frequent and severe
hepatitis during antituberculosis treatment.5 However, the
viral hepatitis status in this study was mainly obtained by
history taking rather than by blood sampling. The authors
should discuss this limitation.
Third, a recent study showed that the initial viral load of
hepatitis B virus (HBV) or hepatitis C virus (HCV) may
influence the incidence of either drug-induced or virus-
induced hepatitis during antituberculosis treatment.6 If the
authors could stratify HBV or HCV patients according to
viral load, the results would be more informative. In addi-
tion, identifying HBV patients who are at risk of virus-
induced hepatitis and prescribe pre-emptive use of an
antiviral agent may prevent this episode and even subse-
quent hepatic failure.0929-6646/$ - see front matter Copyright ª 2011, Elsevier Taiwan LLC
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